1. Home
  2. WLDS vs SKYE Comparison

WLDS vs SKYE Comparison

Compare WLDS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wearable Devices Ltd.

WLDS

Wearable Devices Ltd.

N/A

Current Price

$1.29

Market Cap

7.7M

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.55

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLDS
SKYE
Founded
2014
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
6.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
WLDS
SKYE
Price
$1.29
$1.55
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $68.00
AVG Volume (30 Days)
★ 35.8K
22.5K
Earning Date
08-24-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.26
52 Week High
$6.50
$12.96

Technical Indicators

Market Signals
Indicator
WLDS
SKYE
Relative Strength Index (RSI) 37.30 40.04
Support Level $1.18 $0.26
Resistance Level $1.48 $1.66
Average True Range (ATR) 0.11 0.10
MACD 0.02 0.01
Stochastic Oscillator 30.56 8.00

Price Performance

Historical Comparison
WLDS
SKYE

About WLDS Wearable Devices Ltd.

Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: